Conference Correspondent
Here is a review of study results of various medications being reported from different conferences.
Copenhagen, Denmark-Intravenous (IV) iron isomaltoside 1000 (Monofer) demonstrated sustained increases in hemoglobin (Hb) and fewer adverse events compared with oral iron sulphate in patients with chemotherapy-induced anemia (CIA), according to research presented by Gunnar Birgegard, MD, PhD, and colleagues at the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer.
Hollywood, FL-At the National Comprehensive Cancer Network 20th Annual Conference, Mario E. Lacouture, MD, Associate Professor of Dermatology at Weill Cornell Medical College, and an Associate Attending Physician at Memorial Sloan Kettering Cancer Center, New York, NY, presented some clinical pearls that can guide the management of dermatologic toxicities.
Anders Mellemgaard, MD, Medical Oncologist from the Department of Oncology, Herlev University Hospital, Herlev, Denmark, spoke with The Oncology Pharmacist about his study, "Antiangiogenic-Specific Adverse Events in Patients with Non-Small-Cell Lung Cancer Treated with Nintedanib and Docetaxel," regarding the development of the new compound that is augmenting the effect of chemotherapy by treating the new vasculature.
In order to navigate the increasingly collaborative healthcare landscape, pharmacists need to find a place at the table, according to a presentation at the annual Hematology/Oncology Pharmacy Association conference.
The addition of nintedanib to docetaxel therapy did not increase the frequency of adverse events associated with antiangiogenic treatment in non-small-cell lung cancer (NSCLC) patients, according to research presented at the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting.
The Annual Meeting of the American Society of Clinical Oncology (ASCO) is the largest and most important oncology specialty meeting in the United States, and arguably the world. More than 30,000 oncology professionals gathered in Chicago, IL, to hear about ground-breaking research, state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. Below is a selection of presentations from oral abstracts, posters, and the ASCO education sessions that will be of interest to oncology nurses and advanced practitioners.
Rolapitant 180 mg significantly reduced symptoms of chemotherapy-induced nausea and vomiting in patients treated with multiple cycles of highly or moderately emetogenic chemotherapy when compared with placebo in 4 double-blind, active-controlled studies.
Lindsey B. Amerine, PharmD, MS, BCPS, discussed her practice’s process for formulary management and procurement of oncology medications at the 11th annual Hematology/Oncology Pharmacy Association conference.
Gunnar Birgegård, MD, PhD, discussed his team’s research comparing intravenous iron isomaltoside 1000 with oral iron sulphate monotherapy in patients with cancer and chemotherapy-induced anemia at the 2015 International Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Symposium on Supportive Care in Cancer.